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Although metabolic anomalies are often seen in advanced
chronic kidney disease (CKD), their presence in more mild
states is unknown. We studied 6722 participants in the Third
National Health and Nutrition Examination Survey, dividing
them into three mutually exclusive groups consisting of
those having a normal or mildly reduced estimated
glomerular filtration rate (eGFR) (Modification of Diet in Renal
Disease (MDRD) formula), those with normal or elevated
serum cystatin C, and those with clinically relevant moderate
or severely reduced eGFR (stage 3 or 4 of CKD). The
prevalence of several metabolic abnormalities associated
with moderate to advanced CKD was determined after
standardization for age, race–ethnicity, and gender. In the
absence of stage 3 or 4 CKD, patients with elevated serum
cystatin C had a higher prevalence of low hemoglobin and
elevated uric acid, homocysteine, phosphorus, fibrinogen,
and C-reactive protein than patients with a normal serum
cystatin C. Our results show that in adults with normal or
mildly reduced eGFR, elevated serum cystatin C is associated
with an increased prevalence of metabolic abnormalities
traditionally found in moderate or severe CKD. Elevated
serum cystatin C may identify patients with ‘preclinical’
kidney disease not detected by traditional serum creatinine
measurements.
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Patients with end-stage renal disease experience a high
burden of metabolic abnormalities that may contribute to
their increased morbidity and mortality.1–3 In addition,
several studies have found that adults with stage 3 chronic
kidney disease (CKD) are more likely to have multiple
metabolic abnormalities including anemia, elevated uric acid,
and high homocysteine.4–7 Among patients with CKD, the
presence of these abnormalities is associated with an
increased risk of cardiovascular disease.8,9
Serum cystatin C is a low molecular weight protein that is
freely filtered by the glomerulus and reabsorbed and
metabolized by the proximal tubule. It has been hypothesized
that elevated serum cystatin C in the absence of stages 3
through 5 CKD may represent an early stage of kidney
disease.10 This condition, ‘pre-clinical kidney disease,’ has
been associated with an increased risk of developing stage 3
CKD as well as cardiovascular disease morbidity and
mortality.10,11
If elevated serum cystatin C in the context of an estimated
glomerular filtration rate (eGFR) X60 ml/min per 1.73 m2
represents early kidney disease, we hypothesized that the
metabolic abnormalities traditionally seen in stages 3 through
5 CKD would be more common in these adults than their
counterparts with an eGFR X60 and normal cystatin C. To
further understand the importance of elevated serum cystatin
C as a marker of early kidney disease, we compared levels of
nine metabolic factors for US adults with and without
elevated serum cystatin C who were free of stages 3 through 5
CKD.
RESULTS
Compared with their counterparts with normal cystatin C,
participants with elevated cystatin C and stage 3 or 4 CKD
were older and more likely to be non-Hispanic white (Table 1,
top panel). Participants with stage 3 or 4 CKD were less likely
to be male compared with their counterparts with normal
cystatin C. After age, race-ethnicity, and sex standardization,
participants with elevated cystatin C and stage 3 or 4 CKD
were less likely to have a high school education and more
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likely to be physically inactive, and have hypertension than
participants with normal cystatin C. Current cigarette
smoking was more common among participants with
elevated cystatin C. Mean body mass index (BMI) and
systolic blood pressure were higher and high-density
lipoprotein-cholesterol was lower among participants with
elevated cystatin C and stage 3 or 4 CKD compared with
those with normal cystatin C. Total cholesterol and diastolic
blood pressure were higher and diabetes mellitus was more
common among participants with stage 3 or 4 CKD.
The age, race-ethnicity, and sex-standardized levels of uric
acid, homocysteine, phosphorus, fibrinogen, and C-reactive
protein levels were progressively higher among adults with
elevated cystatin C and stage 3 or 4 CKD (Table 1, middle
panel). In contrast, trends of lower mean levels of
hemoglobin, albumin and bicarbonate levels were present
for adults with elevated cystatin C and stage 3 or 4 CKD
compared with those with normal cystatin C. The age, race-
ethnicity, and sex-standardized prevalence of all metabolic
factors studied, except low ionized calcium, was significantly
higher for adults with elevated cystatin C and stage 3 or 4
CKD (Table 1, bottom panel).
After adjustment for age, race-ethnicity, sex, education,
physical inactivity, current and former smoking, BMI, total
Table 1 | Characteristics of study participants (top panel), mean levels of metabolic parameters (middle panel), and prevalence
of metabolic abnormalities (bottom panel) by cystatin C and CKD status
Population characteristics
Normal cystatin C
(n = 4570)
Elevated cystatin C
(n = 1218)
Stage 3 or 4 CKD
(n = 934) P-trend
Age, years 41.8 (0.7) 64.9 (1.1)*** 70.0 (0.9)*** o0.001
Non-Hispanic white, % 75.1 84.1*** 86.3*** o0.001
Non-Hispanic black, % 11.4 8.4* 7.2*** 0.021
Mexican-American, % 5.5 2.5*** 1.4*** o0.001
Male, % 51.2 54.9 36.7*** 0.009
High school education, % 76.7 (1.7) 65.3 (2.8)*** 66.1 (3.4)** o0.001
Physically inactive, % 20.3 (1.2) 33.8 (3.2)*** 27.4 (3.1)** o0.001
Current smoker, % 28.0 (1.3) 42.4 (4.5)*** 26.1 (3.6) 0.061
Body mass index, kg/m2 26.4 (0.2) 28.7 (0.4)*** 28.3 (0.3)*** o0.001
Total cholesterol, mg per 100 ml 203.5 (1.1) 205.2 (2.7) 220.6 (2.7)*** o0.001
HDL-cholesterol, mg per 100 ml 50.7 (0.5) 45.3 (0.7)*** 46.4 (1.2)*** o0.001
Systolic BP, mm Hg 122.6 (0.5) 125.8 (1.1)** 129.2 (0.9)*** o0.001
Diastolic BP, mm Hg 74.6 (0.3) 75.6 (0.5) 76.6 (0.7)** 0.002
Hypertension, % 21.0 (1.4) 29.9 (2.6)** 34.4 (1.9)*** o0.001
Diabetes mellitus, % 4.4 (0.4) 8.4 (1.9) 9.9 (1.4)*** o0.001
Mean levels of metabolic parameters
Serum hemoglobin, mg per 100 ml 14.3 (0.1) 14.2 (0.1) 14.0 (0.1)*** o0.001
Serum uric acid, mg per 100 ml 5.27 (0.04) 5.92 (0.09)*** 6.72 (0.07)*** o0.001
Serum homocysteinea, mmol/l 9.0 (8.7–9.4) 10.7 (10.2–11.2)*** 12.7 (11.9–13.5)*** o0.001
Serum ionized calcium, mmol/l 1.13 (0.01) 1.15 (0.02) 1.15 (0.02) 0.383
Serum phosphorous, mg per 100 ml 3.42 (0.02) 3.50 (0.03)* 3.52 (0.03)*** o0.001
Serum albumin, mg per 100 ml 4.20 (0.02) 4.10 (0.03)*** 4.14 (0.03)* 0.001
Serum bicarbonate, mmol/l 28.0 (0.3) 28.0 (0.3) 27.3 (0.4)** 0.005
Plasma fibrinogen, mg per 100 ml 297.8 (3.6) 318.8 (5.2)*** 333.5 (6.4)*** o0.001
Serum C-reactive proteina, mg per 100 ml 0.28 (0.27–0.29) 0.37 (0.33–0.41)*** 0.39 (0.35–0.42)*** o0.001
Prevalence of metabolic abnormalities
Low serum hemoglobin, o12 g per 100 ml for women;
o13 g per 100 ml for men
4.3% 8.2%*** 13.8%*** o0.001
Elevated serum uric acid, X5.9 mg per 100 ml for women;
X7.4 mg per 100 ml for men
12.6% 30.0%*** 45.0%*** o0.001
High serum homocysteine, X13mmol/l 12.1% 25.1%*** 41.0%*** o0.001
Low serum ionized calcium, o1.17 mmol/l 15.8% 14.7% 15.2% 0.573
High serum phosphorous, X3.9 mg per 100 ml 17.2% 23.2%* 25.8%** 0.002
Low serum albumin, p3.8 g per 100 ml, 14.5% 20.0%** 20.4%*** o0.001
Low serum bicarbonate, o22 mmol/l 16.5% 19.2% 26.2%** 0.006
High plasma fibrinogen, X352 mg per 100 ml 10.5% 21.7%*** 23.2%*** o0.001
Serum C-reactive protein
Detectable, 0.22–0.99 mg per 100 ml 21.3% 28.5%** 32.2%*** 0.003
Elevated, X1.0 mg per 100 ml 7.5% 22.5%*** 21.6%*** o0.001
BP, blood pressure; CKD, chronic kidney disease; HDL, high-density lipoprotein; ref, reference.
Numbers in table are means (s.e.) or percentages.
All characteristics except age, race-ethnicity, and sex are age, race-ethnicity, and sex standardized.
aValues given are geometric means (95% confidence interval).
*Po0.05, **Po0.01, ***Po0.001 compared with participants with normal cystatin C.
Normal cystatin C: estimated glomerular filtration rateX60 ml/min per 1.73 m2 and serum cystatin Co1.09 mg/l; elevated cystatin C: estimated glomerular filtration rateX60
and serum cystatin C X1.09 mg/l; stage 3 or 4 CKD: estimated glomerular filtration rate o60 ml/min per 1.73 m2 based on the MDRD Study equation.
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and high-density lipoprotein-cholesterol, systolic blood
pressure and diabetes mellitus, trends in prevalence ratios
were present for all metabolic factors except low serum
ionized calcium, low serum bicarbonate and detectable
C-reactive protein (Table 2). Compared to normal cystatin
C, elevated cystatin C was associated with an increased
prevalence of low hemoglobin and high uric acid, homo-
cysteine, phosphorus, fibrinogen, and elevated C-reactive
protein. With the addition of elevated cystatin C and stage 3
or 4 CKD status into the multivariable adjusted model, the
area under the receiver operator characteristic (ROC) curve
for discriminating individuals with and without metabolic
abnormalities increased from 0.709 to 0.748 for low
hemoglobin, from 0.695 to 0.742 for elevated uric acid, and
from 0.688 to 0.752 for high homocysteine (Table 3). Smaller
increases in the area under the ROC curve were present for
low serum albumin, low serum bicarbonate, and high plasma
fibrinogen.
Stratification by age showed that 91.5, 5.6, and 2.9% of the
participants under the age of 70 years and 41.2, 30.6, and
28.2% of participants aged 70 years and older were in
the normal cystatin C, elevated cystatin C, and stage 3 or 4
Table 2 | Multivariable-adjusted prevalence ratios of metabolic abnormalities associated with elevated cystatin C and chronic
kidney disease (CKD)
Prevalence ratio (95% confidence interval)
Normal cystatin C
(n = 4570)
Elevated cystatin C
(n = 1218)
Stage 3 or 4 CKD
(n = 934) P-trend
Low serum hemoglobin, o12 g per 100 ml for women;
o13 g per 100 ml for men
1.00 (ref) 2.10 (1.41–3.14)*** 3.89 (2.85–5.30)*** o0.001
Elevated serum uric acid, X5.9 mg per 100 ml for women;
X7.4 mg per 100 ml for men
1.00 (ref) 1.83 (1.43–2.32)*** 2.80 (2.37–3.30)*** o0.001
High serum homocysteine, X13 mmol/l 1.00 (ref) 1.90 (1.25–2.90)** 3.34 (2.53–4.41)*** o0.001
Low serum ionized calcium, o1.17 mmol/l 1.00 (ref) 0.96 (0.76–1.20) 0.99 (0.80–1.22) 0.793
High serum phosphorous, X3.9 mg per 100 ml 1.00 (ref) 1.38 (1.02–1.86)* 1.60 (1.22–2.11)** 0.002
Low serum albumin, p3.8 g per 100 ml, 1.00 (ref) 1.17 (0.95–1.43) 1.29 (1.07–1.54)** 0.010
Low serum bicarbonate, o22 mmol/l 1.00 (ref) 1.02 (0.65–1.59) 1.49 (1.11–2.01)** 0.063
High plasma fibrinogen, X352 mg per 100 ml 1.00 (ref) 1.67 (1.30–2.15)** 1.76 (1.46–2.13)*** o0.001
Serum C-reactive protein
Detectable, 0.22–0.99 mg per 100 ml 1.00 (ref) 1.03 (0.86–1.23) 1.17 (0.99–1.38) 0.056
Elevated, X1.0 mg per 100 ml 1.00 (ref) 1.79 (1.26–2.54)*** 1.86 (1.32–2.63)*** o0.001
Ref, reference.
Prevalence ratios include adjustment for age, race–ethnicity, sex, education, physical inactivity, current and former smoking, body mass index, total and high-density
lipoprotein–cholesterol, systolic blood pressure, and diabetes mellitus
*Po0.05; **Po0.01; ***Po0.001 compared with participants with normal cystatin C.
No CKD: estimated glomerular filtration rate X60 ml/min per 1.73 m2 and serum cystatin C o1.09 mg/l; elevated cystatin C: estimated glomerular filtration rate X60 and
serum cystatin C X1.09 mg/l; stage 3 or 4 CKD: estimated glomerular filtration rate o60 ml/min per 1.73 m2.
Table 3 | Area under the receiver operator characteristic curve for discriminating participants with and without each metabolic
abnormality
Area under the receiver operator curve (s.e.)
Model does not include elevated
cystatin C and stages 3–4 CKD
Model includes elevated
cystatin C and stages 3-4 CKD P-value
Low serum hemoglobin, o12 g per 100 ml for women;
o13 g per 100 ml for men
0.709 (0.011) 0.748 (0.011) o0.001
Elevated serum uric acid, X5.9 mg per 100 ml for women;
X7.4 mg per 100 ml for men
0.695 (0.010) 0.742 (0.009) o0.001
High serum homocysteine, X13 mmol/l 0.688 (0.009) 0.752 (0.009) o0.001
Low serum ionized calcium, o1.17 mmol/l 0.589 (0.017) 0.590 (0.017) 40.999
High serum phosphorous, X3.9 mg per 100 ml 0.573 (0.013) 0.581 (0.013) 0.162
Low serum albumin, p3.8 g per 100 ml 0.677 (0.008) 0.681 (0.008) 0.046
Low serum bicarbonate, o22 mmol/l 0.623 (0.011) 0.632 (0.011) 0.051
High plasma fibrinogen, X352 mg per 100 ml 0.627 (0.011) 0.644 (0.010) o0.001
Serum C-reactive protein
Detectable, 0.22–0.99 mg per 100 ml 0.672 (0.007) 0.673 (0.008) 0.317
Elevated, X1.0 mg per 100 ml 0.712 (0.014) 0.728 (0.012) o0.001
CKD, chronic kidney disease; s.e., standard error.
Each model includes age, race–ethnicity, sex, education, physical inactivity, current and former smoking, body mass index, total and high-density lipoprotein-cholesterol,
systolic blood pressure, and diabetes mellitus.
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CKD groupings, respectively. The associations of elevated
cystatin C and stage 3 or 4 CKD with metabolic
abnormalities were markedly consistent when stratified by
age group (Figure 1).
Sensitivity analysis
Among participants with an eGFR X60 based on the
Modification of Diet in Renal Disease (MDRD) study
equation, five patients with normal cystatin C and 868 with
elevated cystatin C had an eGFR o60 ml/min per 1.73 m2
based on a recently published age, race, sex, and cystatin
C-based GFR estimating equation.12 After re-categorizing
these participants from the normal and elevated cystatin
C groups to the stage 3 or 4 CKD group, trends of increased
multivariable-adjusted prevalence ratios from normal cysta-
tin C to stage 3 or 4 CKD were present for all metabolic
factors studied except low serum ionized calcium, low serum
bicarbonate, and detectable C-reactive protein (Table 4).
Among participants with an eGFR X60 based on the
MDRD study equation, 475 patients with normal cystatin C
and 254 with elevated cystatin C had albuminuria. Re-
categorizing these participants into an albuminuria group,
did not affect substantially the prevalence ratios of metabolic
abnormalities associated with elevated cystatin C and stage 3
or 4 CKD (Table 5).
DISCUSSION
This study documents a significant increased prevalence of
several metabolic factors among adults with elevated cystatin
C. The low levels of hemoglobin and elevated levels of uric
acid, homocysteine, phosphorus, fibrinogen, and C-reactive
protein have been noted among patients with stages 3
through 5 CKD. The current data extends earlier observations
and documents an increased prevalence of these metabolic
abnormalities among a large representative sample of adults
with elevated serum cystatin C who were free of stages 3
through 5 CKD. These associations were also present among
participants over the age of 70 years despite stage 3 or 4 CKD
and elevated cystatin C being very common in this age group
and among individuals without albuminuria.
CI, confidence interval; PR, prevalence ratio; ref, reference. 
P-values are P -trend across cystatin C and chronic kidney disease categories
Prevalence ratios include adjustment for age, race–ethnicity, sex, education, physical inactivity, current and former smoking, body mass index, total and HDL-cholesterol, systolic
blood pressure, and diabetes mellitus
Normal cystatin C, estimated glomerular filtration rate 60 ml/min per 1.73 m2 and serum cystatin C <1.09 mg per 100 ml; Elevated cystatin C, estimated glomerular filtration rate 60 and
serum cystatin C 1.09 mg per 100 ml; Stage 3 or 4 CKD, estimated glomerular filtration rate <60 ml/min per 1.73 m2 
Age <70 years Age 70 years
Normal cystatin C
Elevated cystatin C
Stage 3 or 4 CKD
Normal cystatin C
Elevated cystatin C
Stage 3 or 4 CKD
Normal cystatin C
Elevated cystatin C
Stage 3 or 4 CKD
Normal cystatin C
Elevated cystatin C
Stage 3 or 4 CKD
Normal cystatin C
Elevated cystatin C
Stage 3 or 4 CKD
Normal cystatin C
Elevated cystatin C
Stage 3 or 4 CKD
Normal cystatin C
Elevated cystatin C
Stage 3 or 4 CKD
Normal cystatin C
Elevated cystatin C
Stage 3 or 4 CKD
Normal cystatin C
Elevated cystatin C
Stage 3 or 4 CKD
Normal cystatin C
Elevated cystatin C
Stage 3 or 4 CKD
Low-serum hemoglobin
Elevated serum uric acid
High-serum homocysteine
Low-serum-ionized calcium
High-serum-phosphorous
Low-serum albumin
Low-serum bicarbonate
High plasma fibrinogen
Detectable CRP
Elevated CRP
Prevalence ratio
1.00 (ref)
1.00 (ref)
1.00 (ref)
1.00 (ref)
1.00 (ref)
1.00 (ref)
1.00 (ref)
1.00 (ref)
1.00 (ref)
1.00 (ref)
PR  (95% CI)
2.09 (1.23 – 3.55)
4.10 (2.68 – 6.25)  P<0.001 
1.66 (1.17 – 2.35)
2.48 (1.90 – 3.24)  P<0.001
1.81 (0.90 – 3.64)
3.25 (2.18 – 4.85)  P<0.001
0.88 (0.64 – 1.20)
1.03 (0.78 – 1.36)  P=0.705
1.60 (1.07 – 2.39)
1.89 (1.32 – 2.71)  P<0.001
1.03 (0.77 – 1.38)
1.39 (1.06 – 1.82)  P=0.074
1.00 (0.58 – 1.72)
1.23 (0.83 – 1.82)  P=0.489
1.70 (1.22 – 2.37)
1.64 (1.25 – 2.15)  P<0.001
0.92 (0.68 – 1.25)
1.03 (0.76 – 1.40)  P=0.885
1.59 (1.00 – 2.53)
1.42 (0.87 – 2.32)  P=0.045
Prevalence ratio
1.00 (ref)
1.00 (ref)
1.00 (ref)
1.00 (ref)
1.00 (ref)
1.00 (ref)
1.00 (ref)
1.00 (ref)
1.00 (ref)
1.00 (ref)
1.62 (1.11 – 2.36)
3.08 (2.14 – 4.44)  P<0.001
2.16 (1.65 – 2.83)
3.27 (2.53 – 4.23)  P<0.001
2.23 (1.74 – 2.86)
3.98 (3.05 – 5.19)  P<0.001
1.07 (0.80 – 1.44)
1.01 (0.78 – 1.30)  P=0.905
1.10 (0.84 – 1.44)
1.25 (0.96 – 1.63)  P=0.094
1.13 (0.91 – 1.40)
1.19 (0.98 – 1.44)  P=0.069
1.20 (0.77 – 1.87)
1.85 (1.17 – 2.93)  P=0.010
1.52 (1.12 – 2.06)
1.77 (1.33 – 2.36)  P<0.001
1.17 (0.98 – 1.40)
1.43 (1.14 – 1.80)  P=0.003
1.77 (1.22 – 2.57)
2.55 (1.75 – 3.71)  P<0.001
PR  (95% CI)
0.50 1.0 2.0 3.0 5.0 0.50 1.0 2.0 3.0 5.0
Figure 1 | Age-stratified multivariable-adjusted prevalence ratios of metabolic abnormalities associated with elevated cystatin C
and stage 3 or 4 chronic kidney disease.
84 Kidney International (2009) 76, 81–88
o r i g i n a l a r t i c l e P Muntner et al.: Serum cystatin C and metabolic abnormalities
Many of the metabolic abnormalities evaluated, including
low levels of hemoglobin and high levels of phosphorus,
homocysteine, uric acid, and fibrinogen, elevated C-reactive
protein, were more common among adults with stage 3 or 4
CKD compared with their counterparts without stage 3 or 4
CKD but with elevated serum cystatin C. These trends
support the hypothesis that elevated cystatin C in the context
of an eGFR X60 ml/min per 1.73 m2 may represent a less
severe form of kidney disease compared with stage 3 or 4
CKD. In addition, elevated cystatin C may be useful for
identifying patients with kidney disease who are not being
detected by serum creatinine. This may include older and
frail adults who typically have low serum creatinine levels.
Although the role of cystatin C as a marker of kidney disease
Table 4 | Sensitivity analysis assessing the multivariable-adjusted prevalence ratios of metabolic abnormalities associated with
elevated cystatin C and stage 3 or 4 chronic kidney disease based on the MDRD study equation or a cystatin C, age, sex, race
equation
Normal cystatin C
(n = 4565)
Elevated cystatin C
(n = 350)
Stage 3 or 4 CKDa
(n = 1807) P-trend
Low serum hemoglobin, o12 g per 100 ml for women;
o13 g per 100 ml for men
1.00 (ref) 2.03 (1.04–3.97)* 3.05 (2.22–4.18)*** o0.001
Elevated serum uric acid, X5.9 mg per 100 ml for women;
X7.4 mg per 100 ml for men
1.00 (ref) 1.60 (1.05–2.44)* 2.46 (2.10–2.89)*** o0.001
High serum homocysteine, X13 mmol/l 1.00 (ref) 1.85 (0.81–4.24) 2.67 (1.99–3.59)*** o0.001
Low serum ionized calcium, o1.17 mmol/l 1.00 (ref) 0.48 (0.24–0.96)* 1.00 (0.73–1.36) 0.654
High serum phosphorous, X3.9 mg per 100 ml 1.00 (ref) 1.57 (1.03–2.39)* 1.40 (1.10–1.78)** 0.005
Low serum albumin, p3.8 g per 100 ml, 1.00 (ref) 1.22 (0.84–1.77) 1.22 (1.03–1.43)* 0.019
Low serum bicarbonate, o22 mmol/l 1.00 (ref) 0.93 (0.50–1.72) 1.32 (0.95–1.83) 0.166
High plasma fibrinogen, X352 mg per 100 ml 1.00 (ref) 1.09 (0.70–1.70) 1.92 (1.54–2.38)*** o0.001
Serum C-reactive protein
Detectable, 0.22–0.99 mg per 100 ml 1.00 (ref) 1.09 (0.76–1.56) 1.08 (0.94–1.25) 0.052
Elevated, X1.0 mg per 100 ml 1.00 (ref) 1.83 (1.10–3.05)* 1.80 (1.31–2.48)*** o0.001
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ref, reference.
aOn the basis of an eGFR o60 ml/min per 1.73 m2 using the MDRD study equation33 or eGFR o60 ml/min per 1.73 m2 using the cystatin C, age, sex, race-based estimating
equation.12
Prevalence ratios include adjustment for age, race-ethnicity, sex, education, physical inactivity, current and former smoking, body mass index, total and high-density
lipoprotein-cholesterol, systolic blood pressure, and diabetes mellitus.
*Po0.05; **Po0.01; ***Po0.001 compared with participants with normal cystatin C.
Normal cystatin C: estimated glomerular filtration rateX60 ml/min per 1.73 m2 and serum cystatin Co1.09 mg/l; elevated cystatin C: estimated glomerular filtration rateX60
and serum cystatin C X1.09 mg/l; stage 3 or 4 CKD: estimated glomerular filtration rate o60 ml/min per 1.73 m2.
Table 5 | Sensitivity analysis assessing the multivariable-adjusted prevalence ratios of metabolic abnormalities associated with
elevated cystatin C, albuminuria, and chronic kidney disease (CKD)
Prevalence ratio (95% confidence interval)
Normal cystatin C
(n = 4095)
Elevated cystatin C
(n = 964)
Albuminuria
(n = 729)
Stages 3–4 CKD
(n = 934)
Low serum hemoglobin, o12 g per 100 ml for women;
o13 g per 100 ml for men
1.00 (ref) 1.85 (1.15–2.96)* 0.91 (0.60–1.39) 3.44 (2.50–4.72)***
Elevated serum uric acid, X5.9 mg per 100 ml for women;
X7.4 mg per 100 ml for men
1.00 (ref) 1.72 (1.25–2.37)** 1.33 (1.04–1.71)* 2.74 (2.29–3.29)***
High serum homocysteine, X13 mmol/l 1.00 (ref) 1.80 (1.17–2.77)** 2.09 (1.31–3.32)** 3.64 (2.74–4.85)***
Low serum ionized calcium, o1.17 mmol/l 1.00 (ref) 0.96 (0.69–1.35) 1.07 (0.74–1.54) 1.03 (0.70–1.51)
High serum phosphorous, X3.9 mg per 100 ml 1.00 (ref) 1.35 (0.97–1.87) 0.73 (0.51–1.03) 1.50 (1.12–2.00)**
Low serum albumin, p3.8 g per 100 ml, 1.00 (ref) 1.25 (0.99–1.56) 1.38 (1.10–1.73)** 1.38 (1.14–1.68)**
Low serum bicarbonate, o22 mmol/l 1.00 (ref) 1.08 (0.67–1.74) 1.24 (0.88–1.76) 1.58 (1.18–2.11)**
High plasma fibrinogen, X352 mg per 100 ml 1.00 (ref) 1.52 (1.14–2.01)** 1.17 (0.78–1.75) 1.67 (1.37–2.05)***
Serum C-reactive protein
Detectable, 0.22–0.99 mg per 100 ml 1.00 (ref) 1.05 (0.86–1.30) 0.94 (0.71–1.25) 1.16 (1.00–1.34)*
Elevated, X1.0 mg per 100 ml 1.00 (ref) 2.12 (1.40–3.23)*** 1.49 (1.00–2.23) 1.96 (1.39–2.79)***
Ref, reference.
Prevalence ratios include adjustment for age, race–ethnicity, sex, education, physical inactivity, current and former smoking, body mass index, total and high-density
lipoprotein–cholesterol, systolic blood pressure, and diabetes mellitus.
*Po0.05; **Po0.01; ***Po0.001 compared with participants normal cystatin C.
Normal cystatin C: estimated glomerular filtration rate X60 ml/min per 1.73 m2, urinary albumin to urinary creatinine ratio o30 mg/g, and serum cystatin C o1.09 mg/l;
elevated cystatin C: estimated glomerular filtration rate X60 ml/min per 1.73 m2, urinary albumin to urinary creatinine ratio o30 mg/g, and serum cystatin C X1.09 mg/l;
albuminuria: estimated glomerular filtration rate X60 ml/min per 1.73 m2 and urinary albumin to urinary creatinine ratio X30 mg/g; stage 3 or 4 CKD: estimated glomerular
filtration rate o60 ml/min per 1.73 m2.
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is still being defined, this study provides an additional
impetus for future studies to evaluate the effect of elevated
serum cystatin C on risk for the development of stages 3
through 5 CKD and cardiovascular disease.
Despite the large prevalence ratios of metabolic abnorm-
alities associated with elevated cystatin C and stages 3–4 CKD,
the area under the ROC curves showed only moderate
improvements for discriminating individuals with and with-
out metabolic abnormalities. This is consistent with earlier
studies showing that large effects (for example, odds ratios
416) are needed to substantially increase the area under the
ROC curve.13 In addition, established cardiovascular disease
risk factors, including lipids, hypertension, and smoking,
have only marginal effects on the area under the ROC curves,
yet lead to more accurate reclassification of patients into
higher-risk or lower-risk categories.14,15 Given the strong
association between elevated cystatin C and metabolic
abnormalities traditionally present in more advanced kidney
disease, the discriminative value of elevated cystatin C in
models developed to determine the presence of metabolic
abnormalities warrants further investigation.
The limitations of using mild elevations in serum
creatinine and small reductions in eGFR as markers of
kidney disease are well documented.16 Many studies,
including two meta-analyses, have reported that serum
cystatin C, compared with serum creatinine, may be a better
marker of kidney function.17,18 However, most of these
studies focused on serum creatinine rather than equations
incorporating demographics. A large study among patients
with CKD suggests that cystatin C provides a better estimate
of GFR than serum creatinine alone but a similar estimate to
the MDRD study equation.12 However, at higher GFR, serum
creatinine estimates are less precise and cystatin C provides
more valid estimates.19,20 Thus, cystatin C provides promise
as a marker for early kidney dysfunction with a higher
sensitivity than serum creatinine-based estimates. However,
there are several lines of evidence that suggest serum cystatin
C may have extra-renal sources. Serum cystatin C has been
shown to be associated with demographics, BMI, thyroid
function, and corticosteroid administration.21–25 There may
be additional potential mechanisms for the presence of
metabolic abnormalities associated with serum cystatin C,
observed in this study, above and beyond kidney function.
The current findings have important public health and
clinical implications as 8.1% of US adults, X20 years of age,
without CKD have a serum cystatin C X1.09 mg/l.26
Epidemiological studies have documented an increased
incidence of cardiovascular disease among adults with
elevated serum cystatin C.10,11,27 Furthermore, progression
to stage 3 or 4 CKD is more common among adults with,
compared with their counterparts without, elevated serum
cystatin C.10 The current analysis highlights an unfavorable
metabolic profile among adults who are free of stage 3 or 4
CKD but have elevated serum cystatin C. These associations
were present after separating out participants with albumi-
nuria. Although the metabolic factors we studied are quite
common in patients with stage 3 or 4 CKD, the presence of
these metabolic abnormalities in adults with elevated cystatin
C in the absence of CKD has not been well characterized
previously and provides a motivation for understanding the
role elevated cystatin C has as an early marker of CKD.
The associations between elevated cystatin C and meta-
bolic abnormalities were present for younger and older
adults. Earlier studies have reported that the magnitude of
the association between low eGFR and increased mortality is
larger for younger adults.28,29 Furthermore, age-specific cut-
points for defining the presence of CKD have been proposed.
The current data highlight that elevated cystatin C and stage
3 or 4 CKD in older individuals is not a benign condition.
Specifically, study participantsX70 years of age with elevated
cystatin C and stage 3 or 4 CKD were more likely to have
several metabolic abnormalities present than participants
with normal cystatin C.
The major limitation of this study is its cross-sectional
design. Our analysis cannot identify the timing or cause of
elevated cystatin C or stage 3 or 4 CKD. Although we cannot
rule out both elevated cystatin C and the metabolic
abnormalities being a consequence of common risk factors,
CKD is known to cause all of the metabolic abnormalities
studied and milder kidney dysfunction detected by cystatin C
may as well. Future studies should endeavor to determine the
effect of the increased burden of these factors on the
progression of kidney disease and the incidence of cardio-
vascular disease as well as the effect of therapies targeting
these abnormalities. Despite this limitation, this study has
several strengths including its large sample size, its complex
sampling design that permits estimates for the non-
institutionalized US adult population, and collection of
multiple metabolic factors. In addition, all NHANES III (the
Third National Health and Nutrition Examination Survey)
data were collected using the standardized procedures
following strict quality control protocols.
In conclusion, this study documents that elevated serum
cystatin C, in the absence of stage 3 or 4 CKD, is associated
with a higher prevalence of low hemoglobin and elevated uric
acid, homocysteine, phosphorus, fibrinogen, and C-reactive
protein. These findings suggest that, in the context of eGFR
levels X60 ml/min per 1.73 m2, elevated serum cystatin C is
associated with many of the abnormalities present in
moderate to advanced CKD.
MATERIALS AND METHODS
The Third National Health and Nutrition Examination Survey was
conducted by the National Center for Health Statistics of the
Centers for Disease Control and Prevention between 1988 and 1994.
A detailed description of the study participants and methods of
NHANES III has been published elsewhere.30 In brief, a stratified
multistage probability design was used to obtain a representative
sample of the civilian non-institutionalized US general population.
Using stored specimens, serum cystatin C was measured on a sample
of 6951 adult participants including all NHANES III participants 60
years and older and a random sample of those 20–59 years of age.21
In addition, cystatin C was measured in all men and women with a
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serum creatinine X1.2 and 1.0 mg per 100 ml, respectively. The
current analysis was limited to adult NHANES III participants aged
20 years or older. Owing to the small number of participants with
stage 5 CKD (that is, eGFR o15 ml/min per 1.73 m2; n¼ 19), they
were excluded from all analyses. In addition, pregnant women
(n¼ 210) were excluded from all analyses. After these exclusions, the
main analyses were based on data from 6722 participants.
The Third National Health and Nutrition Examination Survey
data were collected by administration of a standardized question-
naire during a home interview followed by a detailed physical
examination with collection of blood specimens at a mobile
examination center. Questionnaires were used to collect information
on demographics, education, physical activity, cigarette smoking,
and medication use for diabetes mellitus and hypertension. The
presence of diabetes mellitus was based on patient self-report of a
previous diagnosis. On the basis of the self-report, participants who
had not taken part in 30 or more minutes of moderate or vigorous
activity or any strength training in the 30 days preceding their study
visit were categorized as being physically inactive. Body weight and
height were measured and BMI was calculated as weight in
kilograms divided by height in meters squared. Participants were
classified as having hypertension if, based on the average of six blood
pressure measurements, they had a systolic blood pressure
X140 mm Hg and/or diastolic blood pressure X90 mm Hg, and/or
they reported currently using antihypertensive medication.
The laboratory procedures used in the NHANES III are described
in detail elsewhere.31 Serum phosphorus, bicarbonate, albumin, and
uric acid were measured using a Hitachi 737 automated analyzer
(Boehringer Mannheim Diagnostics, Indianapolis, IN, USA). In
addition, ionized calcium was measured using a NOVA 7þ 7
electrolyte analyzer (NOVA Biomedical, Waltham, MA, USA) and
the values were normalized for serum pH. Hemoglobin levels were
measured using an automated hematology analyzer (Coulter S-Plus
JR; Beckman Coulter Inc., Fullerton, CA, USA). Serum homo-
cysteine was measured by high-performance liquid chromatography,
plasma fibrinogen using enzyme assay methods, and serum
C-reactive protein levels using latex-enhanced nephelometry. Plasma
fibrinogen was measured in study participants aged 40 years and
older. Serum homocysteine levels were measured during the second
phase of NHANES III (1991–1994). The low hemoglobin was
defined using the World Health Organization cut-points of o12 g
per 100 ml for women ando13 g per 100 ml for men. Owing to the
marked gender difference in levels, elevated serum uric acid was
defined as values exceeding the gender-specific 85th percentile
(X5.9 mg per 100 ml for women andX7.4 mg per 100 ml for men).
Serum homocysteine, phosphorus, and plasma fibrinogen were
defined as elevated if greater than or equal to the 85th percentile
(X13 mmol/l, Z3.9, and X352 mg per 100 ml, respectively),
whereas serum ionized calcium, albumin, and bicarbonate levels
were defined as decreased when they were less than the value for the
15th percentile (o1.17 mmol/l, o3.8 g per 100 ml, and o22 mmol/l,
respectively) for this nationally representative sample. Because a
majority of participants studied had a C-reactive protein level below
the detection limit for the assay used (0.22 mg per 100 ml),
C-reactive protein levels were categorized as being undetectable
(o0.22 mg per 100 ml), detectable (0.22–0.99 mg per 100 ml), or
clinically elevated (X1.00 mg per 100 ml).
Serum cystatin C was measured using an automated particle-
enhanced nephelometric assay on the Dade Behring Nephelometer
II (Deerfield, IL, USA). This assay maintains a range from 0.23 to
7.25 mg/l and intra-assay and inter-assay coefficients of variation of
2.0–3.0 and 3.2–4.4%, respectively. Elevated serum cystatin C was
defined as X1.09 mg/l. This level represents the 99th percentile of
the serum cystatin C distribution for NHANES III participants aged
20–39 years without hypertension, diabetes mellitus, micro- or
macro-albuminuria, or stages 3–5 CKD. A percentile-based cut-
point was chosen, as it reflects a level rare among young healthy
adults and is robust to cystatin C assay calibration differences, which
may exist across laboratories. Serum creatinine was measured by the
modified kinetic Jaffe reaction and re-calibrated to calculate eGFR
using the MDRD Study formula.32,33 Urinary albumin was
measured using a solid-phase fluorescence immunoassay; urinary
creatinine was measured using modified kinetic method of Jaffe
(Beckman Coulter Synchron AS/Astra Analyzer, Brea, CA, USA).
Albuminuria was defined as a urinary albumin to urinary creatinine
ratio X30 mg/g.
The protocol for NHANES III was approved by the Institutional
Review Board of the National Center for Health Statistics. Informed
consent was obtained from each NHANES III participant.
Statistical analysis
Participants were categorized into three mutually exclusive groups
for the primary analyses: eGFR X60 ml/min per 1.73 m2 and serum
cystatin C o1.09 mg/l (normal cystatin C), eGFR X60 ml/min per
1.73 m2 and serum cystatin C X1.09 mg/l (elevated cystatin C), and
eGFR between 15 and 59 ml/min per 1.73 m2 (stage 3 or 4 CKD).
Age, race-ethnicity, sex-standardized characteristics, and mean levels
(geometric mean for variables with a skewed distribution) of the
metabolic parameters were calculated for participants in these three
groups. The metabolic abnormalities studied were dichotomized as
present or absent, and the age, race-ethnicity, sex-standardized
prevalence were determined for participants with normal cystatin C,
elevated cystatin C, and stage 3 or 4 CKD. Trends across the three
groupings were assessed using least squares and maximum like-
lihood estimates for continuous and dichotomous variables,
respectively. Prevalence ratios for the presence of the metabolic
abnormalities were calculated, using participants with normal
cystatin C as the reference, after adjustment for age, race-ethnicity,
sex, education, physical inactivity, current and former smoking,
BMI, total and high-density lipoprotein-cholesterol, systolic blood
pressure and diabetes mellitus. The multivariable-adjusted preva-
lence ratios were calculated overall and stratified by age grouping
(o70 andX70 years of age). To determine the discriminative ability
of elevated cystatin C and stage 3 or 4 CKD to identify the presence
of metabolic abnormalities, we calculated the area under the ROC
curve for multivariable-adjusted models including and not includ-
ing elevated cystatin C and stage 3 or 4 CKD. The statistical
significance of differences in the area under the ROC curve between
models including, and not including, elevated cystatin C and stage 3
or 4 CKD were calculated using a 500 iteration bootstrap.
Two sensitivity analyses were conducted. First, the multivariable-
adjusted prevalence ratios for the presence of the metabolic
abnormalities were calculated for adults with elevated cystatin C
and stage 3 or 4 CKD, compared with normal cystatin C, after
including participants with an eGFRo60 ml/min per 1.73 m2 based
on the MDRD Study equation or a newly published age, race, sex,
and cystatin C-based GFR estimating equation in the stage 3 or 4
CKD group.12 Second, participants with albuminuria were stratified
into a separate category. For this analysis, the multivariable-adjusted
prevalence ratios for the presence of the metabolic abnormalities
were calculated for adults with elevated cystatin C (urinary albumin
to urinary creatinine ratio o30 mg/g, eGFR X60 ml/min per
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1.73 m2, and cystatin C X1.09 mg/l), albuminuria (eGFR X60 ml/
min per 1.73 m2 and urinary albumin to urinary creatinine ratio
X30 mg/g), and stage 3 or 4 CKD (eGFRo60 ml/min per 1.73 m2),
compared with the participants with normal cystatin C (urinary
albumin to urinary creatinine ratio o30 mg/g, eGFR X60 ml/min
per 1.73 m2, and cystatin C o1.09 mg/l).
Data were analyzed using SUDAAN (version 9.0; Research
Triangle Institute, Research Triangle Park, NC, USA) to account for
the complex sampling design of NHANES III, including unequal
probabilities of selection, over-sampling, non-response, and mea-
surement of serum cystatin C, in a subsample of participants.
Standard statistical packages do not have commands for the
calculation of the area under the ROC curve for complex survey
data. Therefore, these calculations were performed applying the
sample weights in NHANES III using SAS (version 9.1, Cary, NC,
USA). A bootstrap technique was used to obtain valid standard error
estimates for the area under the ROC curve.
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